30.60
price down icon1.73%   -0.54
after-market 시간 외 거래: 30.60
loading
전일 마감가:
$31.14
열려 있는:
$30.64
하루 거래량:
604.40K
Relative Volume:
0.64
시가총액:
$2.51B
수익:
$399.58M
순이익/손실:
$-54.04M
주가수익비율:
-40.80
EPS:
-0.75
순현금흐름:
$40.13M
1주 성능:
-4.79%
1개월 성능:
-3.83%
6개월 성능:
-7.61%
1년 성능:
+57.33%
1일 변동 폭
Value
$30.18
$31.05
1주일 범위
Value
$30.18
$32.32
52주 변동 폭
Value
$19.09
$47.32

Veracyte Inc Stock (VCYT) Company Profile

Name
명칭
Veracyte Inc
Name
전화
(650) 243-6300
Name
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
직원
824
Name
트위터
@veracyte
Name
다음 수익 날짜
2025-02-24
Name
최신 SEC 제출 서류
Name
VCYT's Discussions on Twitter

VCYT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Diagnostics & Research icon
VCYT
Veracyte Inc
30.60 2.51B 399.58M -54.04M 40.13M -0.75
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
421.85 169.62B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
184.96 138.06B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
406.65 32.79B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
100.26 29.99B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
141.22 26.61B 15.41B 1.37B 2.11B 7.50

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-20 개시 Craig Hallum Buy
2024-12-05 다운그레이드 Goldman Buy → Neutral
2024-11-15 개시 Wolfe Research Outperform
2024-10-16 개시 UBS Buy
2024-10-10 개시 Guggenheim Buy
2024-02-23 재확인 Needham Buy
2023-01-18 다운그레이드 Raymond James Outperform → Mkt Perform
2023-01-05 개시 Scotiabank Sector Outperform
2022-01-07 개시 Stephens Overweight
2021-11-18 재개 Goldman Buy
2021-06-15 개시 Raymond James Outperform
2021-02-18 재개 Needham Buy
2021-01-28 개시 Truist Buy
2020-11-10 개시 KeyBanc Capital Markets Sector Weight
2020-09-09 개시 Morgan Stanley Underweight
2019-07-31 개시 Lake Street Buy
2019-07-02 개시 Needham Buy
2018-11-29 다운그레이드 Janney Buy → Neutral
2018-10-31 업그레이드 Janney Neutral → Buy
2017-11-07 다운그레이드 Janney Buy → Neutral
2017-11-07 다운그레이드 Piper Jaffray Overweight → Neutral
2017-08-31 재개 BTIG Research Buy
2016-11-14 재개 Leerink Partners Outperform
2015-12-18 개시 Cantor Fitzgerald Buy
2015-06-11 재확인 Leerink Partners Outperform
2013-11-26 개시 William Blair Outperform
모두보기

Veracyte Inc 주식(VCYT)의 최신 뉴스

pulisher
04:43 AM

Veracyte data joins NCI SEER database for research By Investing.com - Investing.com India

04:43 AM
pulisher
04:05 AM

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - Business Wire

04:05 AM
pulisher
Apr 18, 2025

Should You Continue to Hold Veracyte Stock in Your Portfolio? - MSN

Apr 18, 2025
pulisher
Apr 16, 2025

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 | VCYT Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 - Business Wire

Apr 16, 2025
pulisher
Apr 15, 2025

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Apr 15, 2025
pulisher
Apr 14, 2025

Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance

Apr 14, 2025
pulisher
Apr 10, 2025

Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Veracyte (VCYT) Just Overtook the 20-Day Moving Average - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? - Nasdaq

Apr 10, 2025
pulisher
Apr 09, 2025

Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating - Investing.com Australia

Apr 09, 2025
pulisher
Apr 08, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.

Apr 08, 2025
pulisher
Apr 07, 2025

Veracyte Scores Relative Strength Rating Upgrade; Hits Key Threshold - MSN

Apr 07, 2025
pulisher
Mar 28, 2025

Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey

Mar 28, 2025
pulisher
Mar 26, 2025

9 AI News and Ratings on Investors’ Radar - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo

Mar 26, 2025
pulisher
Mar 25, 2025

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net

Mar 25, 2025
pulisher
Mar 25, 2025

Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Veracyte (VCYT) Shares Cross Above 200 DMA - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Veracyte says new data demonstrate accuracy of WGS-based platform - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer - Marketscreener.com

Mar 25, 2025
pulisher
Mar 20, 2025

5 Analysts Assess Veracyte: What You Need To Know - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Craig-Hallum initiates Veracyte stock with Buy, sets $45 target By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Craig-Hallum initiates Veracyte stock with Buy, sets $45 target - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Craig-Hallum Initiates Veracyte at Buy With $45 Price Target -March 20, 2025 at 07:28 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - BioSpace

Mar 20, 2025
pulisher
Mar 19, 2025

Veracyte's Decipher, MRD tests highlights to be presented at EAU25 -March 19, 2025 at 05:05 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical StudiesNew Product Coming - StockTitan

Mar 19, 2025
pulisher
Mar 13, 2025

Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally? - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Analyst Sees Bottom For Myriad Genetics Stock, Issues UpgradeMyriad Genetics (NASDAQ:MYGN) - Benzinga

Mar 12, 2025
pulisher
Mar 11, 2025

Veracyte’s chief commercial officer John Leite sells $234,629 in stock By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 10, 2025

Veracyte’s chief commercial officer John Leite sells $234,629 in stock - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Veracyte (VCYT) Surged on Reporting Strong Earnings - Insider Monkey

Mar 10, 2025
pulisher
Mar 09, 2025

Veracyte Inc to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 08, 2025

Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality - Simply Wall St

Mar 08, 2025
pulisher
Mar 08, 2025

29,779 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Proficio Capital Partners LLC - Defense World

Mar 08, 2025

Veracyte Inc (VCYT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
diagnostics_research DGX
$161.86
price down icon 1.18%
diagnostics_research WAT
$316.23
price down icon 1.49%
diagnostics_research LH
$212.22
price down icon 2.26%
$142.23
price down icon 3.95%
diagnostics_research MTD
$970.15
price down icon 3.46%
diagnostics_research IQV
$141.22
price down icon 1.87%
자본화:     |  볼륨(24시간):